All ideas Top 10 Trending Top 100 Business Ideas Top Google Searches Free to start AI businesses Kids and teens 🔒 Blind Spot Index

High Ticket Potential AI-Friendly High Profit Health Tech

Build Radiology Triage and Notification Software (QAS)

People search: “how to build AI stroke detection triage software” (600+ per month)

Build standalone computer-assisted triage and notification software (the FDA QAS product code) that flags time-critical findings like stroke or pulmonary embolism for urgent radiologist review, sold to hospitals per site or per study.

If you typed how to build AI stroke detection triage software into Google, you are in the right place. This is the honest version of that path: the real work, the real costs, and the real way in.

⚡ Faster with AI: the platform's AI can do the heavy lifting on this idea (content, plan, pages, outreach), so it comes to life quicker than building it all by hand.

✨ Customize this idea to me 📖 Read the full playbook ↓

Keep browsing: All ideas · Top 10 · AI businesses · Free to start · More Health Tech

Difficulty

Advanced

Startup cost

$500,000 to $5,000,000-plus for clinical AI R&D, FDA clearance, and hospital deployment

Time to first $

540 days and up

Revenue potential

Very High

Profit margin

SaaS gross margin high; long clinical-validation and sales cycles weigh on net early

Viability ⓘ

6.5 / 10

Search demand

Medium (600+ per month on Google)

Where it runs

Online

Best for: Clinical-AI teams pairing machine learning, radiology expertise, and regulatory capability

The ideaWhat this actually is

This is a standalone artificial-intelligence medical device in the FDA computer-assisted triage and notification category (product code QAS). It analyzes an imaging study the moment it is acquired, detects whether a time-critical finding is likely present (classically large-vessel-occlusion stroke on a head CT or pulmonary embolism on a chest CT), and if so moves that study to the top of the radiologist's worklist and pushes a notification to the treating team so the sickest patients are seen first. Crucially, it triages rather than diagnoses: the radiologist still makes and owns the read, and the tool is about speed and prioritization, not replacing clinical judgment. It is sold to hospitals and imaging centers as software, typically per site or per study on subscription, and it must be cleared by the FDA (almost always through the 510(k) pathway) and integrated into the hospital's PACS, worklist, and communication systems to work. It sits in the single densest AI regulatory category in all of medicine.

The opportunityWhy this idea works

Radiology is unambiguously the epicenter of medical AI commercialization: it accounts for roughly 76 percent of all FDA-authorized AI-enabled medical devices, with 1,104 radiology-specific devices cleared, more than every other specialty combined, and QAS triage is one of its most active sub-categories, with nine new clearances in a single mid-2025 update. The reason is that the clinical value is unusually clear and measurable: in stroke and pulmonary embolism, minutes change outcomes, so a tool that reliably pushes those cases to the front of the queue and alerts the team has a concrete, defensible value story that hospitals will pay for. The 510(k) pathway that about 97 percent of radiology AI uses gives a faster route to clearance than most medical devices enjoy. And because the finding is narrow and the value is time-to-treatment, a focused, well-validated tool can win on quality before larger portfolios catch up. The category is proven, active, and buyer-motivated.

The openingWhy this idea is overlooked

Generalist founders skip this because every signal says do not enter: it is regulated as a medical device, it needs clinical validation, it needs radiologists on the team, and it must be integrated into hospital systems that are famously hard to integrate with. That wall of difficulty hides a paradoxical fact: this is the most-cleared category of AI in all of medicine. Radiology alone holds about three-quarters of every AI device the FDA has authorized, and triage-and-notification is one of its hottest slices. The barriers are real, but they are barriers to everyone, which is exactly what makes a cleared, well-integrated, well-validated tool defensible. The people who could build it (clinical-AI teams) often assume the space is already saturated, while the documented reality is that only about 5 percent of cleared radiology AI has been prospectively tested, meaning there is enormous room to compete on genuine evidence rather than just another clearance.

The buildWhat you need to build this

You need	Why it matters
A focused, well-validated algorithm	Start with one or a few time-critical findings (stroke, PE) where earlier detection changes outcomes. Performance across diverse populations and scanners is what earns clinical trust and clearance, so narrow and excellent beats broad and mediocre.
Large, diverse, well-labeled imaging data	Model quality and real-world generalization depend on the training and validation data. Biased or narrow data produces a tool that fails on the populations and scanners it was not trained on, which hospitals will discover.
FDA regulatory capability	The tool is a medical device and almost always clears via 510(k) (the pathway about 97 percent of radiology AI uses). You need regulatory expertise from the start because clearance gates every sale.
Clinical validation beyond clearance	Only about 5 percent of cleared radiology AI has been prospectively tested. Sophisticated hospital buyers increasingly demand real evidence, so validation is both a sales asset and a moat, not just a checkbox.
Hospital worklist and notification integration	The tool must flag findings inside the radiologist's actual worklist and notify the care team through existing systems. Integration with PACS and communication paths is where deployments live or die.
Radiology and clinical expertise on the team	You are building a clinical tool whose value is time-to-treatment. Radiologist and clinical input shapes the product, the validation, and the credibility buyers require.
Patience and capital for long cycles	Clinical AI has long validation, clearance, and enterprise sales cycles. You need funding to survive the gap between building the tool and reaching scaled revenue.

How to build AI stroke detection triage software: the honest path

So if you have been wondering about how to build AI stroke detection triage software, the steps below are the real answer, minus the hype.

The roadmap

How to start, step by step

1
Understand the QAS category and what it does
Computer-assisted triage and notification software (the FDA QAS product code) analyzes a scan and flags time-critical findings (such as large-vessel-occlusion stroke or pulmonary embolism) so those patients move to the top of the radiologist's worklist and the care team is notified fast. It triages; it does not replace the radiologist's diagnosis. This category had nine new FDA clearances in a single mid-2025 update, making it one of the most active in medical AI. Design your product around speed-to-treatment, which is its clinical value.
2
Pick the finding and build the algorithm
Start focused: one or a few time-critical findings where earlier detection changes outcomes. Build the model on large, well-labeled, diverse imaging datasets, because performance across real-world populations and scanners is what determines clinical trust and regulatory success. Narrow and excellent beats broad and mediocre for a first clearance.
3
Clear the FDA pathway and validate honestly
About 97 percent of radiology AI clears through the 510(k) predicate-equivalence pathway, which is faster than de novo or PMA. But only about 5 percent of cleared radiology AI has been prospectively tested, a documented evidence gap. Clearing is not the same as proving clinical value, so plan the clearance you need and the validation your hospital buyers will demand, which is more.
4
Integrate into the hospital worklist and notification path
The tool is worthless if it cannot flag findings inside the radiologist's actual worklist and notify the stroke or PE team through existing channels. Integration with PACS, the worklist, and hospital communication systems is where deployments succeed or die, and it is its own hard problem (see the legacy-integration card). Budget heavily for real-world integration.
5
Sell to hospitals on speed and outcomes
Buyers are hospitals, health systems, and imaging centers, and they buy on faster time-to-treatment for stroke and PE, better worklist prioritization, and demonstrated outcomes. Price per site or per study on subscription. Reference sites and outcome data drive the long enterprise sales cycle, so land strong early adopters and publish results.
6
Plan for the bundling and consolidation reality
Health systems suffer integration fatigue from deploying many single-finding tools, which is pushing the market toward multi-finding bundled platforms (a separate card) and toward acquisition by larger AI portfolios or device makers. Decide whether you stay a focused best-in-class tool, expand into a bundle, or aim to be acquired. That strategic choice shapes your roadmap and funding.

The traps

Common mistakes that kill this business

Mistake	What happens
Treating FDA clearance as proof of clinical value	A cleared tool that sophisticated hospitals still reject because it lacks the prospective evidence they now demand, since only about 5 percent of cleared radiology AI has been prospectively tested
Underinvesting in worklist and notification integration	An accurate algorithm that never reaches the radiologist in time or the care team at all, which is the same as not working
Training on narrow or biased data	A tool that performs in the demo and fails on real-world populations and scanners, destroying clinical trust and reference sites
Trying to detect everything at once	A diluted, hard-to-validate product that clears slowly and underperforms focused competitors on the findings that matter
Ignoring integration fatigue and bundling pressure	A single-finding tool stranded as health systems consolidate onto multi-finding platforms or acquire portfolios, leaving you without a channel

The money

How this idea makes money

Per-site subscription

Hospitals and imaging centers pay an annual per-site license for the tool running across their scanners, giving you predictable recurring revenue.

Per-study pricing

Charge per scan analyzed, aligning cost with usage, which can lower the barrier to adoption for lower-volume sites.

Multi-finding expansion

Add findings over time and sell an expanding bundle, raising per-site value and responding to health systems that want fewer vendors (the multi-finding platform strategy).

Enterprise and health-system contracts

Sell system-wide deployments to large health systems on outcomes and standardization, the largest and stickiest contracts in the space.

Acquisition by a portfolio or device maker

Larger AI portfolios and scanner manufacturers routinely acquire focused, cleared, well-validated tools to grow their authorization count, a realistic and common exit.

Prove it to yourself

Run the numbers on this idea

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Recurring revenue calculator →Subscription pricing calculator →All 33+ calculators

The start

Your first 7 days

Day 1Choose the single time-critical finding to start with (for example large-vessel-occlusion stroke or pulmonary embolism) based on clinical impact and data access.

Day 2Map the FDA landscape for that finding: existing QAS clearances, likely predicates, and what a 510(k) would require.

Day 3Assess data access: what labeled, diverse imaging datasets you can obtain or partner for, since data is the constraint on model quality.

Day 4Recruit or confirm radiology and regulatory expertise on the team, because both are prerequisites, not later hires.

Day 5Sketch the integration reality: how the tool will reach the worklist and notify the care team through hospital PACS and communication systems.

Day 6Draft the validation plan beyond clearance: how you will generate the prospective, real-world evidence buyers now expect.

Day 7Decide the strategic posture: focused best-in-class tool, future multi-finding bundle, or build-to-acquire, and align the roadmap to it.

The fit

Who this is for, and who it is not for

Best for: Clinical-AI teams pairing machine learning, radiology expertise, and regulatory capability

Not for: This is not for someone seeking a fast, low-capital launch. It is a regulated medical-device business with long validation, clearance, and enterprise sales cycles and real clinical-safety stakes. If you want radiology AI adjacent work without building a device, consider the AI validation-audit service, the performance-heterogeneity consultancy, or the 510(k) pathway strategy firm, all separate cards here.

Your first move

Build and clinically validate an algorithm that detects one or a few time-critical findings, clear it through the FDA (usually the 510(k) QAS pathway), integrate it into hospital worklists so it flags and notifies, and sell per site or per study.

🔒 The rest of the playbook is free

The step-by-step roadmap, the traps that kill this business, how it makes money, and your first 7 days. A free account unlocks every playbook forever, plus saving ideas and the tools to build this one.

Unlock the full playbook free →

Already a member? Log in and this opens.

The shortcut

Where Unleash Your Ideas comes in

Unleash Your Ideas can help you scope the focused first finding, the honest validation plan, and the integration and go-to-market path that turn a cleared algorithm into a tool hospitals actually deploy.

Three ways to act on this idea

Do it yourself

Use the platform free to turn this idea into your own execution plan: niche, offer, money path, and first steps.

Unleash This Idea Free

Guided

Get our team's help shaping the strategy, the setup, and the launch path with you.

Get Help Setting It Up

Done for you

Apply to have the strategy and buildout done with you or for you, with vetted specialists managed by one team.

Done For You

Make it yours

Customize this idea to me

Create your free account, Build Radiology Triage and Notification Software (QAS) gets stored as YOURS, and Kenny, your AI build partner, rewrites the proven Unleash an Idea path around your version of it. Every idea you bring after this gets the same treatment.

✨ Customize this idea to me →

Keep browsing

Related ideas

Build a Multi-Finding Bundled Triage Platform →

Advanced · $1,000,000 to $10,000,000-plus for a portfolio of validated, cleared algorithms and a deployment platform · Viability 6.6/10

Build a Pure-Play Radiology AI Vendor →

Advanced · $5,000,000 to tens of millions across a multi-product portfolio, clearances, and enterprise sales · Viability 6.1/10

Build Imaging Risk-Prediction Biomarker Software →

Advanced · $500,000 to $5,000,000-plus for model development, validation, and regulatory strategy · Viability 6.0/10

Build a Clinical-Grade CBT Chatbot for Health Systems and National Health Services →

Advanced · $500,000 to $10,000,000+ for clinical development, trials, and regulatory work · Viability 6.5/10

Build Point-of-Care Ultrasound AI Guidance Software →

Advanced · $500,000 to $5,000,000-plus for model development, device integration, and FDA clearance · Viability 6.4/10

Build an AI Oncology Imaging Suite →

Advanced · $500,000 to $5,000,000-plus for model development, validation, and oncology-workflow integration · Viability 6.3/10

Questions

What people ask about this idea

What is a QAS product code?

QAS is the FDA product code for computer-assisted triage and notification software: tools that flag time-critical findings so those patients are prioritized and the care team is notified. It triages and prioritizes; it does not make or replace the radiologist's diagnosis.

Is radiology AI already saturated?

Radiology holds about 76 percent of all FDA-authorized AI devices and triage-notification is very active, so it is crowded, but only about 5 percent of cleared radiology AI has been prospectively tested. There is real room to compete on genuine clinical evidence rather than just another clearance.

Do I need FDA clearance?

Yes. These tools are regulated medical devices and almost always clear through the 510(k) pathway that roughly 97 percent of radiology AI uses. Clearance gates every sale, so regulatory capability is required from the start, not added later.

How is this different from a multi-finding platform?

This card is a focused tool for one or a few time-critical findings. The multi-finding bundled platform detects many conditions from one scan to reduce the integration fatigue hospitals face from deploying many single-purpose tools. They are related strategies and separate cards; a focused tool can expand into a bundle over time.

← Browse all business ideas